Alex Sapir

Alex has served as a member of PhaseBio’s board of directors since February 2020. He has more than 25 years of experience building commercial-stage pharmaceutical organizations and is currently the chief executive officer of ReViral Therapeutics. Prior to ReViral, Alex served as president and chief executive officer at Dova Pharmaceuticals, having previously spent 10 years as executive vice president for United Therapeutics Corporation and seven years in various commercial roles at GlaxoSmithKline. He received a BA in economics from Franklin and Marshall College and an MBA from Harvard Business School.